We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Expected fall highlights challenges for pharmaceutical companies that experienced pandemic windfall
Central American nation was one of Taipei’s last partners in Washington’s backyard
Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots
Health secretary confirms acceptance of advice from expert committee to ‘bridge the gap’ to autumn
Pharma group hopes for approval of mRNA vaccine for booster shots
UK biotech racing to keep antibody up to date with latest variants
Hong Kong-based lender seeks to cater to mainlanders’ demand for western jabs
Pharmaceutical groups to part ways with longstanding executives
South Korean vaccine maker looks elsewhere to expand overseas business
Jab developed by CanSinoBio could help nation grappling with a wave of infection
A surge in cases after China lifted restrictions has sparked concerns that a dangerous new strain could emerge
Beijing rejects Brussels’ offer, citing full control of situation
Explosion of cases and ban on more effective western shots lead residents to look abroad
Authorities have relied on vaccines made using original strain found in Wuhan
Joe Biden’s chief medical adviser urges Beijing to approve use of western vaccines
Nearly 90mn Chinese are insufficiently protected against Covid as Beijing begins to unwind pandemic controls
Plus, Japan look to make history, defensive Dutch plot different course
Joe Biden’s coronavirus tsar says Chinese vaccines are ‘not as good’ as alternatives
Cepi releases blueprint to move three times faster against a new virus than during Covid-19 pandemic
Economic and social costs are climbing but Beijing has failed to offer a way out of endless lockdowns
Plan abandoned almost two years after initial approval in UK and Europe
Ending of pharma group’s IP truce spells fight for future of mRNA technology
Fall from €3.2bn in the third quarter of 2021 to €1.8bn
Jab maker ties weaker revenue outlook to delivery delays and manufacturing issues
Market rallies on hopes of looser coronavirus lockdown measures and travel restrictions
International Edition
